AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 14674497
Drug: Phosphoric acid
RxNorm normalized name: Phosphoric Acid
DrugBank: Phosphoric acid (DB09394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phosphoric acid treatment with Prime & Bond NT on enamel surfaces treated with 27-microm air-particle abrasion
Trial: 14674497
Drug: Phosphoric acid
RxNorm normalized name: Phosphoric Acid
DrugBank: Phosphoric acid (DB09394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phosphoric acid treatment with Prime & Bond NT on enamel surfaces not treated with air-particle abrasion (control)
Trial: 7767525
Drug: Theophylline (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (300 mg twice a day)
Trial: 2191443
Drug: 100 mg/d
RxNorm normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/d oral fluconazole
Trial: 2191443
Drug: 400 mg/d
RxNorm normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg/d ketoconazole
Trial: 2191443
Drug: IV fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV fluconazole 100 to 300 mg/d
Trial: 31381020
Drug: High-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin D3 (2400 IU/d; N = 315)
Trial: 31381020
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose vitamin D3 (400 IU/d; N = 308)
Trial: 26400188
Drug: Berberine hydrochloride
RxNorm normalized name: Berberine Hydrochloride
DrugBank: Berberine (DB04115)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Berberine hydrochloride 400 mg, delivered twice daily for 8 weeks
Trial: 23706111
Drug: Guaranà 350
RxNorm normalized name: GUARANA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guaranà 350 mg × 3 daily just after breakfast for 5 consecutive days
Trial: 19583072
Drug: WHO Analgesic
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WHO Analgesic Ladder
Trial: 19583072
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of NSAID and adjuvant treatment
Trial: 11444999
Drug: Methionine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methionine (100 mg/Kg) plus vitamin C (2 g orally)
Trial: 11444999
Drug: Methionine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methionine (100 mg/Kg) plus placebo tablets
Trial: 11444999
Drug: Placebo drink
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drink plus placebo tablets
Trial: 7970045
Drug: 6% neostigmine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% neostigmine (1 puff = 5.4 mg), 2 puffs per nostril, repeated every 4 hours up to 6 puffs/day for 4 days or until canalization of feces and gas was achieved.
Trial: 19890639
Drug: Group 1
RxNorm normalized name: Chlamydophila psittaci biogroup 1 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1 (low-dose)
Trial: 19890639
Drug: Group 2
RxNorm normalized name: Chlamydophila psittaci biogroup 2 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2 (low-dose)
Trial: 12925515
Drug: Biased-coin treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biased-coin treatment allocation rules
Trial: 8856091
Drug: Alternating monthly
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Alternating monthly cycles of IFN-alpha and chemotherapy (group II)
Trial: 1622852
Drug: ARGIMESNA p.o.,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARGIMESNA p.o., 20% of IFO dose every 2 h x 4
Trial: 1622852
Drug: MESNA p.o.,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MESNA p.o., 40% of IFO dose every 4 h x 2
Trial: 31342780
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (language treatment 20 minutes a day, six days/week, for five weeks)
Trial: 27624513
Drug: Collaborative care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collaborative care intervention model with cognitive-behavioral therapy, care management, and psychopharmacological consultation.
Trial: 26842203
Drug: TMX/GOS (Tamoxifen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMX/GOS (Tamoxifen 20 mg/day for 5 years plus Goserelin 3.6 mg injection per month for 2 years)
Trial: 26842203
Drug: TMX (Tamoxifen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMX (Tamoxifen 20 mg/day for 5 years)
Trial: 22677304
Drug: Topical preparations
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical preparations (0.1% tretinoin, 0.1% adapalene, 5% dapsone, 1% clindamycin, benzoyl peroxide with adapalene or clindamycin, clindamycin-tretinoin combination)
Trial: 22677304
Drug: Benzoyl peroxide
RxNorm normalized name: Benzoyl Peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benzoyl peroxide preparations (2 for 2.5%, 3 for 5.0%)
Trial: 22677304
Drug: Vehicle (placebo)
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle (placebo) for benzoyl peroxide preparations
Trial: 22677304
Drug: Overall vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall vehicle contribution toward drug effect
Trial: 20406218
Drug: PF-00821385 (0.5-120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-00821385 (0.5-120 mg kg(‐1))
Trial: 20406218
Drug: PF-00821385 (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-00821385 (administered to 24 volunteers)
Trial: 16278521
Drug: Amlodipine besylate/benazepril
RxNorm normalized name: amlodipine besylate/benazepril 5 mg-10 mg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine besylate/benazepril HCl 5/20 mg combination therapy
Trial: 16687966
Drug: Amlodipine besylate
RxNorm normalized name: Amlodipine Besylate
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine besylate 5 mg
Trial: 16278521
Drug: Benazepril HCl
RxNorm normalized name: benazepril HCl
DrugBank: Benazepril (DB00542)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benazepril HCl 20 mg
Trial: 10442509
Drug: PGE1 (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGE1 (60 microg given daily i.v. over 2 hours in 250 ml saline, n = 12)
Trial: 10442509
Drug: Placebo (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (250 ml saline, n = 12)
Trial: 2349372
Drug: Dexamethasone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (1 mg orally, 14 h before)
Trial: 28762896
Drug: Transdermal glyceryl
RxNorm normalized name: glyceryl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal glyceryl trinitrate (5 mg/day)
Trial: 26923613
Drug: Fluoxetine 20
RxNorm normalized name: fluoxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20 mg/day immediately (Group A)
Trial: 26923613
Drug: Fluoxetine 20
RxNorm normalized name: fluoxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20 mg/day 7 days after enrollment (Group B)
Trial: 26923613
Drug: No fluoxetine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No fluoxetine (Group C)
Trial: 22179140
Drug: DXA scans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DXA scans after daily activities
Trial: 20004725
Drug: Alcohol intoxication
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol intoxication (target blood alcohol level of 50 mg%)
Trial: 17285425
Drug: Fentanyl (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (10 microg/kg at induction and 5 microg/kg/h infusion for maintenance)
Trial: 17285425
Drug: Remifentanil (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (3 microg/kg at induction and 1 microg/kg/min infusion for maintenance)
Trial: 16540790
Drug: Zinc (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc (20 mg orally, once daily for 14 days) with ORS
Trial: 12889593
Drug: NICHD Maternal
RxNorm normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NICHD Maternal Fetal Medicine Units Network trials (specific interventions not detailed)
Trial: 6657514
Drug: Vehicle solution
RxNorm normalized name: compounding vehicle solution sugar free no. 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle solution
Trial: 7855966
Drug: Sublingual liquid
RxNorm normalized name: B Complex with B-12 Sublingual Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual liquid preparation
Trial: 7855966
Drug: Aqueous nasal
RxNorm normalized name: Pen-Aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous nasal spray
Trial: 7855966
Drug: Controlled absorption
RxNorm normalized name: ABSORPTION BASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled absorption 3 and 4 mg tablets
Trial: 7855966
Drug: Home trial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home trial use of controlled absorption tablets
Trial: 7060486
Drug: Subcutaneous heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous heparin administration via jet injector
Trial: 7060486
Drug: Subcutaneous heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous heparin administration via disposable syringe
Trial: 30506427
Drug: Football (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Football (1 hour, twice weekly)
Trial: 28700680
Drug: High frequency
RxNorm normalized name: ALCOHOL 0.7 mL in 1 mL TOPICAL SOLUTION [enMotion Foam High Frequency Use]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High frequency treatment groups
Trial: 28700680
Drug: Low frequency
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low frequency treatment groups
Trial: 25582611
Drug: lidocaine 1.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lidocaine 1.5 mg/kg
Trial: 25582611
Drug: lidocaine 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lidocaine 0.5 mg/kg
Trial: 21593661
Drug: Efavirenz (EFV)
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Efavirenz (EFV) 600 mg once daily
Trial: 21890776
Drug: Nevirapine (NVP)
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nevirapine (NVP) 400 mg once daily (after 14 days of 200 mg)
Trial: 19920270
Drug: Eszopiclone, 3
RxNorm normalized name: Eszopiclone, 3 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eszopiclone, 3 mg for the first 14 nights of CPAP
Trial: 17353335
Drug: Optimal pain
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal pain medication (OPM)
Trial: 14694167
Drug: Epoetin alpha
RxNorm normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epoetin alpha to maintain hemoglobin between 120 and 130 g/L (group A)
Trial: 14694167
Drug: Epoetin alpha
RxNorm normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epoetin alpha to maintain hemoglobin between 90 and 100 g/L (group B)
Trial: 10925934
Drug: 2% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lidocaine with epinephrine 5 microg x mL(‐1) (group E)
Trial: 10925934
Drug: 2% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lidocaine (group L)
Trial: 8873934
Drug: Sidestream smoke
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sidestream smoke inhalation
Trial: 6341271
Drug: Older girls
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Older girls (11-12 years) in treatment group
Trial: 6341271
Drug: Younger boys
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Younger boys (10-11 years) in treatment group
Trial: 29653812
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (2800 IU daily for 8 weeks)
Trial: 25661470
Drug: Nurse-led heart
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nurse-led heart failure specific education session with three-month telephone follow-up in addition to standard medical treatment
Trial: 12423432
Drug: Antibiotics/topical treatments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics/topical treatments
Trial: 8910174
Drug: Metoclopramide 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 0.25 mg/kg IV
Trial: 8910174
Drug: Ondansetron 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 0.15 mg/kg IV
Trial: 1656521
Drug: Standard breakfast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard breakfast with 100 mg miglitol
Trial: 1656521
Drug: Muesli with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Muesli with 100 mg miglitol
Trial: 6391134
Drug: Intravenous timolol
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous timolol treatment
Trial: 22875601
Drug: Secukinumab (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secukinumab (150 mg single dose)
Trial: 8992904
Drug: Rocuronium (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium (0.6 mg/kg)
Trial: 20236598
Drug: Rocuronium +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium + Neostigmine (0.04 mg/kg) and Atropine (0.02 mg/kg)
Trial: 15065961
Drug: 16-week cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16-week cognitive-behavioral treatment for primary anxiety disorders
Trial: 15065961
Drug: Positive responders
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Positive responders to anxiety treatment
Trial: 11876837
Drug: rhGH (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGH (0.1 mg . kg(‐1) subcutaneously at 10 pm every evening for 14 days)
Trial: 8538091
Drug: Bronchodilators only
RxNorm normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bronchodilators only (Control)
Trial: 1286545
Drug: Shortened intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shortened intravenous glucose tolerance test (IVGTT)
Trial: 1286545
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of glucose with model assessment (C.I.G.M.A.)
Trial: 3891346
Drug: Nifedipine treatment
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine treatment (10 mg orally at onset, after 30 min, then every 6 h)
Trial: 30705235
Drug: Multifactorial intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multifactorial intervention including a 2-hour workshop on best-practice regarding BZD prescription, monthly feedback on prescribing practices, and access to a support web page
Trial: 22915730
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (control group, self-reported data)
Trial: 22915730
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (control group, imputed self-reported outcomes)
Trial: 20385632
Drug: HIE-erythropoietin group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIE-erythropoietin group (2500 IU/kg, subcutaneously, daily for 5 days)
Trial: 10205211
Drug: Adrenaline injection
RxNorm normalized name: epinephrine Injection [Adrenalin]
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adrenaline injection
Trial: 10205211
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (adrenaline injection and gold probe)
Trial: 2692728
Drug: Mitoxantrone at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitoxantrone at 14 mg/m2
Trial: 2692728
Drug: Mitoxantrone at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitoxantrone at 8 mg/m2
Trial: 270863
Drug: No prophylactic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No prophylactic treatment (previous series)
Trial: 30874471
Drug: Bolus dose
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus dose epinephrine (BDE)
Trial: 20216298
Drug: Extended-release niacin
RxNorm normalized name: niacin Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release niacin (ERN) 500 mg/night titrated to 1500 mg/night for 12 weeks
Trial: 18065594
Drug: L-Carnitine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Carnitine (2 g levocarnitine once daily)
Trial: 15855557
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg repaglinide
Trial: 15855557
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg and 4 mg repaglinide
Trial: 15855557
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg and 1 mg repaglinide
Trial: 12393571
Drug: Screened patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Screened patients for drug-dependent antibodies (DDABs)
Trial: 10861613
Drug: Subdermal injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subdermal injection of radiotracer on the tumor site plus a second injection of radiotracer (varied by group)
Trial: 10861613
Drug: Different route
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Different route of injection (peritumoral or subdermal) on the tumor site
Trial: 10999057
Drug: Dexamethasone (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (8 mg, 6 hourly for 7 days)
Trial: 31553234
Drug: Olaparib tablets
RxNorm normalized name: Olaparib Tablets
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib tablets (300 mg twice daily) until disease progression, unacceptable toxicity, or another discontinuation criterion.
Trial: 26980371
Drug: LY2495655 105
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY2495655 105 mg
Trial: 26980371
Drug: LY2495655 315
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY2495655 315 mg
Trial: 17336417
Drug: Candesartan cilexetil,
RxNorm normalized name: Candesartan Cilexetil, 4 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan cilexetil, 8 mg/d (N=24)
Trial: 17336417
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (N=23)
Trial: 12015902
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous administration of 12 million international units (MIU) of IL-2 followed by subcutaneous high-dose IL-2 (7.5 MIU, twice daily) for 5 days every 8 weeks
Trial: 12015902
Drug: High-dose subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose subcutaneous IL-2 for 5 days every 8 weeks
Trial: 12015902
Drug: Low-dose (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose (3 MIU, twice daily) subcutaneous IL-2 for 5 days every 4 weeks
Trial: 9562580
Drug: Interferon gamma-1b
RxNorm normalized name: Interferon Gamma-1B
DrugBank: Interferon gamma-1b (DB00033)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon gamma-1b (60 microg per square meter of body-surface area subcutaneously once weekly)
Trial: 10955434
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg oestradiol implants
Trial: 7794850
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg oestradiol implants
Trial: 3371393
Drug: Metoprolol CR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol CR (controlled-release), 100 mg once daily
Trial: 3371392
Drug: Conventional metoprolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional metoprolol tablets, 100 mg once daily
Trial: 3371393
Drug: Metoprolol CR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol CR (controlled-release), 200 mg if needed
Trial: 3371393
Drug: Conventional metoprolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional metoprolol tablets, 200 mg if needed
Trial: 3371393
Drug: All formulations
RxNorm normalized name: Novel Influenza-H1N1-09, all formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All formulations of metoprolol
Trial: 29042333
Drug: IV acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV acetaminophen (1 g every 6 hours up to 18 hours postoperatively)
Trial: 27493113
Drug: Combined treatment:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment: esophagogastric devascularization with splenectomy followed by sclerotherapy (group B)
Trial: 25271603
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of immunologically active gluten daily
Trial: 18235409
Drug: First line
RxNorm normalized name: ALCOHOL 0.75 mL in 1 mL TOPICAL CLOTH [First Line Alcohol Wipes]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First line chemotherapy based on a combination of pemetrexed and cisplatin
Trial: 18235409
Drug: Antiangiogenic agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiangiogenic agents such as bevacizumab (Avastatin)